Accelerating Access to New Treatments

A new Alzheimer’s treatment received FDA approval under the accelerated approval program. Former FDA Associate Commissioner Peter Pitts explains how the accelerated approval pathway leads to incremental innovation, or building blocks to develop the next generation of medicines for all patients. 

Plus, patient advocate Katie Coughlin shares her experience living with Ehlers-Danlos Syndrome (EDS), and why better care coordination could improve outcomes for her and fellow patients living with a rare disease. 

Hosts: 

Terry Wilcox, CEO, Patients Rising

Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest

Guests:

Peter Pitts, Co-Founder and President of the Center for Medicine in the Public Interest

Katie Coughlin, EDS Patient Advocate

Kimberly Gonzalez, Patient Correspondent 

Links: 

A new Alzheimer’s drug will cost $26,500 a year. Who will be able to get it?

Doctors press HHS to loosen test result rule 

Need help?

The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org

Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?

Drop us a line: podcast@patientsrising.org

The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising, nor do the views and opinions stated on this show reflect the opinions of a guest’s current or previous employers.